SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Acutaas Chemicals - Quaterly Results

29 Jan 2026 Evaluate
The sales for the December 2025 quarter moved up 44.26% to Rs. 3908.56 millions as compared to Rs. 2709.44 millions during the corresponding quarter last year.The Net Profit of the company reported a remarkable increase of 146.26% to Rs. 1115.64  millions  from Rs. 453.04 millions in previous same quarter.OP of the company witnessed a marginal growth to 1605.35 millions from 688.22 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 3908.56 2709.44 44.26 9020.20 6856.73 31.55 9898.35 6875.83 43.96
Other Income 63.43 21.66 192.84 313.33 126.41 147.87 183.36 137.86 33.00
PBIDT 1605.35 688.22 133.26 3331.19 1537.27 116.70 2434.78 1214.53 100.47
Interest 8.14 6.08 33.88 20.06 54.75 -63.36 58.57 58.94 -0.63
PBDT 1597.21 682.14 134.15 3311.13 1482.52 123.34 2376.21 838.05 183.54
Depreciation 90.18 56.72 58.99 242.02 174.89 38.38 240.45 146.94 63.64
PBT 1507.03 625.42 140.96 3069.11 1307.63 134.71 2135.76 691.11 209.03
TAX 391.39 172.38 127.05 778.10 340.64 128.42 540.29 254.25 112.50
Deferred Tax 27.83 9.67 187.80 93.74 23.23 303.53 70.58 45.12 56.43
PAT 1115.64 453.04 146.26 2291.01 966.99 136.92 1595.47 436.86 265.21
Equity 409.36 409.34 0.00 409.36 409.34 0.00 409.34 368.81 10.99
PBIDTM(%) 41.07 25.40 61.70 36.93 22.42 64.72 24.60 17.66 39.26

Acutaas Chemicals Share Price

2411.15 49.40 (2.09%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×